IN INTEGRATIVE APPROACH TO TREATMENT AND SECONDARY PREVENTION OF VARIOUS MALIGNANCIES MAKROBIOTIKA U INTEGRATIVNOM PRISTUPU LEČENJU I SEKUNDARNOJ PREVENCIJI KOD RAZNIH MALIGNIH OBOLJENJA Nina ID: 335982
Download Presentation The PPT/PDF document "MACROBIOTICS" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
MACROBIOTICS IN INTEGRATIVE APPROACH TO TREATMENT AND SECONDARY PREVENTION OF VARIOUS MALIGNANCIESMAKROBIOTIKA U INTEGRATIVNOM PRISTUPU LEČENJU I SEKUNDARNOJ PREVENCIJI KOD RAZNIH MALIGNIH OBOLJENJA
Nina
Bulajic
, M.D., Ph.D.
VII Evropski kongres integrativne medicine,
Beograd, oktobar 2014.Slide2
MacrobioticsLifestyle based on ancient Chinese philosophyStaples: principles of the Universe based on YIN, YANG & Five Energy Transformation theory Lifestyle: whole foods, maintenance of chi flow in the body, personal developmentOriginates from Japan (G.Osawa, M.Kushi), developed in XX century in Western countries, especially USASlide3
Macrobiotics in integrative medicineWeiger WA, Smith M, Boon H, Richardson MA, KaptchukTJ, Eisenberg DM. Advising Patients Who Seek Complementary and Alternative Medical Therapies for Cancer. Ann Intern Med, 2002, 137:889-903.Lerman HR. The Macrobiotic Diet in Chronic Disease. Nutr Clin
Pract
2010,25:621-626.
:
C
arefully
planned m
acrobiotic
diet , as part of a healthy lifestyle, can be effective in the prevention of obesity, cardiovascular diseases, diabetes and cancer. It may also be a method of treatment in all these
conditions.Slide4
The aim : Evaluation of macrobiotics in the treatment and secondary prevention of cancer.Cilj:Evaluacija makrobiotike u lečenju i sekundarnojprevenciji kanceraSlide5
Retrospective interventional studyRetrospektivna interventna studijaInclusion criteria: 42
patients diagnosed with various
malignancies who attended the macrobiotic consultations from 2006 – 2014
evaluated
by conventional medicine with complete medical
records
conducted
advice on macrobiotic lifestyle at least 6
months
The
macrobiotic diet was corrected in accordance with the latest scientific knowledge, when it was necessary, especially during chemotherapy
protocols
Kriterijumi za uključenje u studiju: 42 pacijenta sa raznim malignitetima koji su došli na makrobiotičke konsultacije u periodu 2006-2014. i sa potpunom medicinskom dokumentacijom
S
provodili makrobiotički stil života najmanje 6 meseci
Makrobiotička dijeta je korigovana u skladu sa najnovijim naučnim saznanjima kada je bilo potrebno, naročito za vreme hemioterapijeSlide6
Age distribution (starosna distribucija)Age at the reception
No.
of patients
25
- 30
2
30-40
5
40-50
6
50-60
25
60-70
4Slide7
Gender distribution (rodna distribucija)Total (ukupno): 42 patientsFemale (ženski pol): 28 (66,6%)Male (muškarci): 14 (33,4%)Slide8
Localisation of malignancy (lokalizacija maligniteta)Primary localisation
No.
of patients
Breast (dojka)
9
Female
genital organ
s (ženski genitalni organi)
6
Urinary
bladder (mokraćna bešika)
1
Stomack and oesophagus (stomak i jednjak)
5
Colon (debelo crevo)
5
Liver (jetra)
2
Lar
y
n
x (grkljan)
2
Lungs (pluća)
5
Haematolo
gical
malign
ancies (hematološki
maligniteti)
7Slide9
Invasiveness of malignancies (invazivnost maligne bolesti)Invasiveness
No.of
patients
In organ and regional lymph
nodes (u organu i regionalnim limfnim žlezdama)
17
Spreading in local tissues
and distant
lymph
nodes (širenje u lokalna tkiva i udaljene limfne žlezde)
11
M
etastases in distant organs (metastaze u udaljenim organima)
8
Lo
calised
l
y
m
ph
om
as (lokalizovani limfomi)
2
Dif
f
u
se
l
y
m
phomas (difuzni limfomi)
2
Myeloma
multiplex
(multipli mijelom)
1
Policytemia
(policitemija)
1Slide10
Oncological protocols (onkološki protokoli)*Hepatocellular liver cancer; breast cancer
- kancer jetre, kancer dojke
**
Colon a
denokarcinom
a metastatic
in lungs and liver
; mi
crocellular lung carcinoma metastatic in liver
– kancer debelog creva sa metastazama na plućima i jetri, kancer pluća sa metastazama na jetri***NHL (Non Hodžkin limfom) – after the first session of chemotherapy MB applied and no recidive for 3 years
, Myeloma multiplex
–
bone marrow transplantation planned, MB applied, after 7 years no need for conventional medical treatment
Protocol
Completition
Totally
completed (potpuno sproveden)
30 (71,4%)
Partly
recejted
(
C
T
and
/or
radio
th
erapy
)
–delimično odbijen
6
Totally
rejected (potpuno odbijen)
2 *
Lack of indications (bez indikacija)
2**
Unnecessary after a
doption
of macrobiotics (nepotreban nakon primene makrobiotike)
2***Slide11
MB intervention related to course of the diseaseVreme intervencije makrobiotikomIn the course of the disease
(u toku bolesti)
32
After surgery
without CT/ radiotherapy (posle operacije, bez dalje hemo ili radioterapije)
5
In
remission of the disease
(u remisiji)
1
Prevention after completed oncological protocol
(prevencija
nakon kompletno sprovedenog onkološkog protokola)
4Slide12
Favorable outcome of MB intervention – Uspešni ishodCourse of the disease
Malignancy
invasivennes
Medical
protocol
No.of
patients
Slowed
progression
(
relat
ively
favorable out
come)
RELATIVNO USPEŠNI ISHOD
In
organs
In primary
organ and distant metastases
In
organ
In primary
organ and distant metastases
Complete
Complete
No CT
No CT
5
5
1
2
Total
13
P rogression stopped
ZAUSTAVLJENA PROGRESIJA
NHL
in
remission
Myeloma multiplex
Breast cancer
metas
tatic
in bones and lungs
0
0
Hormonal treatment and chemical
castration
1
1
1
Total
3
No
re
lapse up
to
5
years
No
re
lapse
5 do 10
y
6
8Slide13
Favorable outcome (Uspešni ishod)30 out of 42 patients (71,4
%)
–
kod 30 od 42 pacijenta (71,4%)
In
17 patients the progression of the disease
completely halted
or were introduced into remission (56,6% favorable outcome), and in 13 cases the disease progression slowed after adoption of macrobiotics (according to
oncological
assessments in relation to the average of patients who do not carry out this lifestyle) – 43, 4% favorable outcome.
Kod 17 pacijenata progresija bolesti se potpuno zaustavila ili su uvedeni u remisiju (56,6% uspešnih ishoda), a u 13 slučajeva progresija bolesti se usporila (prema onkološkoj proceni u odnosu na prosečne pacijente koji nisu usvojili ovaj način života) – 43,4% uspešnog ishodaSlide14
Patients without relapse up to 5 years (No. 6)Pacijenti bez pojave bolesti do 5 godina
Pa
tient
Malignancy
Med.
t
herapy
Start
of MB
No
re
lapse up to
V.V.
NHL
Non Hodžkin limfom
Complete
At the end of
protocol
1,5
y
S.D.
NHL
Complete
At the beginning of protocol
5
y
D.Z.
NHL
C
omplete
until remission
In
re
mission
3
y
S.V.
Urinary
bladder
Mokraćna bešika
Complete
U
the
course of protocol
2
y
M.D.
Gastric
Želudac
Complete
After
protocol
3,5
y
A.S.
Ovar
ial
Jajnik
Only
surgery
After surgery
2
ySlide15
Patients without relapse more than 5 years (No. 8) Pacijenti bez pojave bolesti više od 5 godina
Pa
tient
Malignancy
Med.
t
herapy
Start of MB
No
relapse
up to
M.Đ.
Cervix – Grlić materice
Complete
After protocol
8
y
J.B.
Colon- Debelo crevo
Surgery
After
surgery
8
y
N.A.
Lar
ynx- Grkljan
Complete
After
protocol
5,5
y
B.V.
Lungs - Pluća
Complete
(
surgery
)
After protocol
10
y
,
6
on
MB
S.K.
Breast - Dojka
Complete
At
the beginning of protocol
8
y
M.LJ:
Uterus
- Materica
Complete
At
the end of protocol
8
y
G.C.
Policytemia
Complete
During
protocol
7
y
J.K.
Myeloma multiplex
Unnecessary
Before
medical treatment
,
1
y after diagnosis
7
ySlide16
Unfavorable outcome after MB intervention12 out of 42 (28,6%)Nepovoljni ishod nakon primene makrobiotike – 12 od 42 pacijenta (28,6%)
Course
of disease
Inva
siveness
of malignancy
Medic
al
protoco
l
No
of patients
No
effect
Bez efekta
In
organ
In
prim
organ
and
distant
metastases
In organ
Complete
Complete
No CT
2
(
lungs
,
ovarial
3
(
lungs
,
colon
,
HL)
2
(
breast
)
Total
7
Progres
sion
in other organs
Progresija u druge organe
Breast
cancer
Stomack
cancer
Larynx
cancer
After
C
T
metasta
ses
in
liver
After
C
T
metasta
ses
in
liver
After
C
T
metasta
ses
in
lungs
1
1
1
Total
3
Relapses
Ponovna
pojava bolesti
Breast
cancer
Colon
cancer
-
CT rejected after surgery
, MB
applied
,
local
recidiv
e
-
After surgery
,
C
T
i
MB
,
remi
ssion
,
after
new
ovarial
cancer
,
CT
repeated
1
1Slide17
The course of the disease related to degree of oncological protocol rejectionTok bolesti u odnosu na odbijanje onkološkog protokola
Pa
tient
Malignancy
Med
.
intervention
Outcome
J.B.
Colon
cancer
Surgery
No
relapse
up to
8
y
A.S.
Breast
cancer
Surgery
No
relapse
up to
2
y
Z.I.
Breast
cancer
CT
,
ceasses
for
negative side effects
MB
with no effect
, let
h
al
outcome
M.K.
Breast
cancer
Surgery
No re
laps
e up to
2
y
,
later unknown
LJ.N.
Breast
cancer
Surgery, CT rejected
MB
with no effect
, let
h
al
o.
J.Š.
Breast
cancer
Surgery,
CT rejected
Lo
c
.
relaps
e
,
afterwards
completed protocoleSlide18
The course of the disease related to degree of oncological protocol rejectionTok bolesti u odnosu na stepen odbijanja onkološkog protokola8 patients had not implemented the proposed oncology protocol. In 2 cases of complete and 2 cases of partial rejection the outcome was lethal, in one case of partial rejection there was a relapse, and in 3 cases of partial rejection of the protocol relapse did not
appear
over 2 years.
8 pacijenata nisu prihvatili preporučeni onkološki protokol. U 2 slučaja potpunog i 2 slučaja delimičnog odbijanja ishod je bio fatalan, u jednom slučaju delimičnog odbijanja bolest se ponovo javila, a u 3 slučaja delimičnog odbijanja protokola bolest se nije javila više od 2 godineSlide19
ConclusionZaključakMacrobiotics is a valuable method of traditional medicine in the secondary prevention of malignancies, and also can be effectively used as a complementary method in the treatment of cancer.Makrobiotika je vredna metoda tradicionalne medicine u sekundarnoj prevenciji malignih bolesti, a takođe i efikasna komplementarna metoda u lečenju kancera.